AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...
Trending: Bristol-Myers Squibb Shares Up on Setback for AbbVie Schizophrenia Drug
Bristol-Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Shares were recently up 11% after AbbVie reported ...
BioSpace1d
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide Moat
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
AbbVie tumbles on drug test disappointment, Bristol-Myers gains
AbbVie (ABBV) shares slide after its schizophrenia drug failed to meet the goals of its mid-stage trial. Shares of ...
BioPharma Dive7d
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Bristol-Myers upgraded at Leerink after AbbVie setback
Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...
What's Going On With Bristol-Myers Squibb Shares Monday?
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...
Seeking Alpha17d
Bristol Myers posts long-term Phase 3 data for schizophrenia drug Cobenfy
Bristol Myers Squibb (NYSE:BMY ... and efficacy of Cobenfy in 156 adults with schizophrenia who had previously received the drug as part of the company’s five-week EMERGENT-2 or EMERGENT ...
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
AbbVie's closely watched schizophrenia drug fails two studies, shares slide
AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...